Aclarion Unveils MR Spectroscopy Application for Detecting Discogenic Pain Biomarkers at Global Neuroscience Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 13 2025
0mins
Should l Buy ACON?
Source: Newsfilter
Panel Discussion at ISPN Annual Meeting: Aclarion, Inc. participated in the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London, focusing on the use of MR Spectroscopy to identify discogenic pain biomarkers, with insights from experts in the field.
Nociscan Technology: Aclarion's Nociscan® is a pioneering SaaS platform that utilizes MR spectroscopy and AI algorithms to help physicians differentiate between painful and non-painful lumbar discs, aiming to improve treatment strategies for chronic low back pain affecting over 266 million people globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACON
Wall Street analysts forecast ACON stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.080
Low
23.00
Averages
23.00
High
23.00
Current: 3.080
Low
23.00
Averages
23.00
High
23.00
No data
About ACON
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aclarion Releases 2026 Shareholder Letter Highlighting Key Milestones
- Strengthened Financial Position: Aclarion's recent financings provide a cash runway into 2028, ensuring that the company can complete its 300-patient CLARITY trial and achieve initial data readout without raising additional capital, thereby boosting shareholder confidence.
- Clinical Trial Progress: The company anticipates an initial internal readout of the CLARITY trial by the end of Q3 2026, with public disclosure of early interim results expected in Q4, which will provide critical data support for its technology in the chronic low back pain market.
- Optimized Capital Structure: Aclarion has terminated its ATM and allowed its ELOC to expire at the end of 2025, indicating that the company will not pursue new capital raises in the near term, further solidifying its clean capital structure.
- Software-Driven Innovation: As a new generation of software-native MedTech innovator, Aclarion's Nociscan platform delivers solutions entirely through the cloud, enabling rapid scalability and continuous algorithmic improvements, which are expected to significantly enhance its competitive position in the market.
See More
Aclarion, Inc. Closes $10.4 Million Financing, Extends Cash Runway to 2028
- Successful Financing: Aclarion closed a $10.4 million common stock financing priced at $5.18 per share, which enhances the company's balance sheet and strategic flexibility, supporting Nociscan's clinical and commercial growth.
- Extended Cash Runway: As of January 12, 2026, the company reported $21.6 million in cash with zero debt, extending its cash runway into 2028 based on current operating plans, ensuring operational capacity ahead of key milestones.
- Accelerated Clinical Validation: Aclarion aims to speed up patient enrollment in the CLARITY trial to approximately 25% by the end of Q2 2026, while also conducting several real-world evidence studies to expand market opportunities by over 30%.
- Technology Upgrade and Market Expansion: The company plans to launch Nociscan version 2.8 in Q1 to improve workflow integration and is actively engaging with multiple U.S. commercial payers to advance broader reimbursement for Nociscan, enhancing its competitive position in the market.
See More
Aclarion Closes $10.4 Million Financing, Extends Cash Runway to 2028
- Successful Financing: Aclarion has closed a $10.4 million common stock financing at $5.18 per share, significantly strengthening the company's balance sheet and ensuring the integrity of its capital structure for future growth.
- Increased Cash Reserves: As of January 12, 2026, Aclarion holds $21.6 million in cash with zero debt, extending its cash runway into 2028, which secures operational stability for the coming years.
- Accelerated Clinical Validation: The company aims to enroll approximately 25% of patients in the CLARITY trial by the end of Q2 2026, with initial results available internally after the three-month follow-up, expediting the clinical validation of Nociscan.
- Market Expansion Strategy: Aclarion plans to grow access to major MRI manufacturers, increasing the global market size by over 30%, while enhancing clinician education and awareness through participation in CME events to further penetrate the market with Nociscan.
See More
Tilray Brands Reports Q2 Earnings Beat, Shares Surge 7.3%
- Earnings Beat: Tilray Brands reported Q2 earnings of $0.01 per share, surpassing the market expectation of a $0.20 loss, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved quarterly revenue of $217.51 million, exceeding the consensus estimate of $210.95 million, demonstrating success in market demand and sales strategies, which further solidifies its market position.
- Stock Price Surge: Following the positive earnings report, Tilray Brands' shares rose 7.3% to $9.80 in pre-market trading, reflecting investor optimism about the company's future growth potential.
- Positive Market Reaction: The strong performance post-earnings release may attract more investor attention, enhancing the company's appeal in a competitive market landscape.
See More
Aclarion (ACON) Shares Surge 50% Following 2025 Business Update and 2026 Outlook
- Performance Growth: Aclarion's Nociscan diagnostic platform saw a 114% year-over-year increase in scan volumes in Q4 2025 and a 69% increase for the full year, significantly enhancing market adoption through expansion into new imaging centers and physician users, thereby boosting the company's revenue potential.
- Financial Stability: The company reported a debt-free balance sheet with $12 million in cash, providing ample financial support for operations and ensuring sustained growth capacity through 2027.
- Clinical Trial Acceleration: Aclarion plans to accelerate patient enrollment in its CLARITY clinical trial in 2026, a move that not only enhances the competitiveness of its product but also lays the groundwork for future revenue growth.
- Strong Market Reaction: On the day of the announcement, ACON's stock opened at $5.75, surged to a high of $8.80, and experienced trading volumes significantly above average, reflecting strong investor interest in the company's operational progress and strategic guidance.
See More
Aclarion Reports 69% Year-over-Year Scan Volume Growth Entering 2026 with Strong Financial Position
- Commercial Momentum: Aclarion's proprietary Nociscan AI platform saw a 69% year-over-year increase in annual scan volumes in 2025, with fourth-quarter volumes up 114% from the previous year, marking three consecutive quarters of growth across U.S., U.K., and European markets, indicating strong market expansion momentum.
- Clinical Validation Progress: The company launched the CLARITY trial in 2025 with seven activated sites, aiming to enroll approximately 25% of patients by the end of Q2 2026, which enhances clinical and economic evidence for Nociscan and positions the company for future commercial expansion.
- Cost-Effectiveness Analysis: A cost-effectiveness analysis published in ClinicoEconomics and Outcomes Research concluded that Nociscan saves $1,712 per patient and improves surgical success rates by 10%, demonstrating its clinical advantages and potentially driving broader market acceptance.
- Strong Financial Position: As of December 31, 2025, Aclarion held $12 million in cash with no debt, extending its operational runway into the first half of 2027, while raising over $22 million in equity financing during the year, thereby strengthening its financial foundation.
See More
Aclarion Releases 2026 Shareholder Letter Highlighting Key Milestones
- Strengthened Financial Position: Aclarion's recent financings provide a cash runway into 2028, ensuring that the company can complete its 300-patient CLARITY trial and achieve initial data readout without raising additional capital, thereby boosting shareholder confidence.
- Clinical Trial Progress: The company anticipates an initial internal readout of the CLARITY trial by the end of Q3 2026, with public disclosure of early interim results expected in Q4, which will provide critical data support for its technology in the chronic low back pain market.
- Optimized Capital Structure: Aclarion has terminated its ATM and allowed its ELOC to expire at the end of 2025, indicating that the company will not pursue new capital raises in the near term, further solidifying its clean capital structure.
- Software-Driven Innovation: As a new generation of software-native MedTech innovator, Aclarion's Nociscan platform delivers solutions entirely through the cloud, enabling rapid scalability and continuous algorithmic improvements, which are expected to significantly enhance its competitive position in the market.
See More
Aclarion, Inc. Closes $10.4 Million Financing, Extends Cash Runway to 2028
- Successful Financing: Aclarion closed a $10.4 million common stock financing priced at $5.18 per share, which enhances the company's balance sheet and strategic flexibility, supporting Nociscan's clinical and commercial growth.
- Extended Cash Runway: As of January 12, 2026, the company reported $21.6 million in cash with zero debt, extending its cash runway into 2028 based on current operating plans, ensuring operational capacity ahead of key milestones.
- Accelerated Clinical Validation: Aclarion aims to speed up patient enrollment in the CLARITY trial to approximately 25% by the end of Q2 2026, while also conducting several real-world evidence studies to expand market opportunities by over 30%.
- Technology Upgrade and Market Expansion: The company plans to launch Nociscan version 2.8 in Q1 to improve workflow integration and is actively engaging with multiple U.S. commercial payers to advance broader reimbursement for Nociscan, enhancing its competitive position in the market.
See More
Aclarion Closes $10.4 Million Financing, Extends Cash Runway to 2028
- Successful Financing: Aclarion has closed a $10.4 million common stock financing at $5.18 per share, significantly strengthening the company's balance sheet and ensuring the integrity of its capital structure for future growth.
- Increased Cash Reserves: As of January 12, 2026, Aclarion holds $21.6 million in cash with zero debt, extending its cash runway into 2028, which secures operational stability for the coming years.
- Accelerated Clinical Validation: The company aims to enroll approximately 25% of patients in the CLARITY trial by the end of Q2 2026, with initial results available internally after the three-month follow-up, expediting the clinical validation of Nociscan.
- Market Expansion Strategy: Aclarion plans to grow access to major MRI manufacturers, increasing the global market size by over 30%, while enhancing clinician education and awareness through participation in CME events to further penetrate the market with Nociscan.
See More
Tilray Brands Reports Q2 Earnings Beat, Shares Surge 7.3%
- Earnings Beat: Tilray Brands reported Q2 earnings of $0.01 per share, surpassing the market expectation of a $0.20 loss, indicating a significant improvement in profitability that boosts investor confidence.
- Revenue Growth: The company achieved quarterly revenue of $217.51 million, exceeding the consensus estimate of $210.95 million, demonstrating success in market demand and sales strategies, which further solidifies its market position.
- Stock Price Surge: Following the positive earnings report, Tilray Brands' shares rose 7.3% to $9.80 in pre-market trading, reflecting investor optimism about the company's future growth potential.
- Positive Market Reaction: The strong performance post-earnings release may attract more investor attention, enhancing the company's appeal in a competitive market landscape.
See More
Aclarion (ACON) Shares Surge 50% Following 2025 Business Update and 2026 Outlook
- Performance Growth: Aclarion's Nociscan diagnostic platform saw a 114% year-over-year increase in scan volumes in Q4 2025 and a 69% increase for the full year, significantly enhancing market adoption through expansion into new imaging centers and physician users, thereby boosting the company's revenue potential.
- Financial Stability: The company reported a debt-free balance sheet with $12 million in cash, providing ample financial support for operations and ensuring sustained growth capacity through 2027.
- Clinical Trial Acceleration: Aclarion plans to accelerate patient enrollment in its CLARITY clinical trial in 2026, a move that not only enhances the competitiveness of its product but also lays the groundwork for future revenue growth.
- Strong Market Reaction: On the day of the announcement, ACON's stock opened at $5.75, surged to a high of $8.80, and experienced trading volumes significantly above average, reflecting strong investor interest in the company's operational progress and strategic guidance.
See More
Aclarion Reports 69% Year-over-Year Scan Volume Growth Entering 2026 with Strong Financial Position
- Commercial Momentum: Aclarion's proprietary Nociscan AI platform saw a 69% year-over-year increase in annual scan volumes in 2025, with fourth-quarter volumes up 114% from the previous year, marking three consecutive quarters of growth across U.S., U.K., and European markets, indicating strong market expansion momentum.
- Clinical Validation Progress: The company launched the CLARITY trial in 2025 with seven activated sites, aiming to enroll approximately 25% of patients by the end of Q2 2026, which enhances clinical and economic evidence for Nociscan and positions the company for future commercial expansion.
- Cost-Effectiveness Analysis: A cost-effectiveness analysis published in ClinicoEconomics and Outcomes Research concluded that Nociscan saves $1,712 per patient and improves surgical success rates by 10%, demonstrating its clinical advantages and potentially driving broader market acceptance.
- Strong Financial Position: As of December 31, 2025, Aclarion held $12 million in cash with no debt, extending its operational runway into the first half of 2027, while raising over $22 million in equity financing during the year, thereby strengthening its financial foundation.
See More
